Table 4.
The concentrations and MR of TAM and its metabolites among different CYP3A5 polymorphisms
| CYP3A5 | n | TAM (ng/mL) | NDMT (ng/mL) | END (ng/mL) | 4OHT (ng/mL) |
|---|---|---|---|---|---|
| Genotype | 133 | p=0.771 | p=0.680 | p=0.844 | p=0.223 |
| CYP3A5*1/*1 | 18 | 363.76 (199.20) | 1,057.48 (682.44) | 51.12 (67.14) | 4.37 (2.35) |
| CYP3A5*1/*3 | 64 | 364.20 (249.26) | 1,049.24 (501.11) | 53.42 (54.21) | 5.03 (2.92) |
| CYP3A5*3/*3 | 51 | 384.02 (235.09) | 1,085.89 (724.63) | 56.22 (49.41) | 5.39 (3.18) |
| Phenotype | 133 | p=0.493 | p=0.451 | p=0.813 | p=0.100 |
| EM | 82 | 363.76 (234.85) | 1,049.24 (553.93) | 53.42 (57.28) | 4.80 (2.86) |
| PM | 51 | 384.02 (235.09) | 1,085.89 (724.63) | 56.22 (49.41) | 5.39 (3.18) |
|
| |||||
| CYP3A5 | n | MR (TAM-NDMT) | MR (NDMT-END) | MR (TAM-4OHT) | MR (4OHT-END) |
|
| |||||
| Genotype | 133 | p=0.307 | p=0.786 | p=0.742 | p=0.642 |
| CYP3A5*1/*1 | 18 | 0.32 (0.10) | 21.72 (30.33) | 79.49 (51.14) | 0.10 (0.15) |
| CYP3A5*1/*3 | 64 | 0.36 (0.10) | 15.45 (23.37) | 70.34 (41.05) | 0.08 (0.09) |
| CYP3A5*3/*3 | 51 | 0.34 (0.09) | 23.26 (19.97) | 63.23 (47.45) | 0.10 (0.08) |
| Phenotype | 133 | p=0.831 | p=0.657 | p=0.508 | p=0.400 |
| EM | 82 | 0.36 (0.10) | 15.89 (25.49) | 71.04 (42.44) | 0.08 (0.12) |
| PM | 51 | 0.34 (0.09) | 23.26 (19.97) | 63.23 (47.45) | 0.10 (0.08) |
Notes: The concentrations of TAM and its metabolites are presented as median (interquartile range). p=p value from Kruskal–Wallis test.
Abbreviations: 4OHT, 4-hydroxytamoxifen; EM, extensive metabolizer; END, endoxifen; IM, intermediate metabolizer; MR, metabolic ratios; NDMT, N-desmethyl tamoxifen; PM, poor metabolizer; TAM, tamoxifen.